Confluence Pharmaceuticals receives $200K investment from IU fund
Confluence Pharmaceuticals develops treatments for social and communication impairments related to autism spectrum disorder, fragile X syndromeCredit: Teri Willey BLOOMINGTON, Ind. -- The Indiana University...









